Literature DB >> 6992593

The distribution of prostaglandins in afferent and efferent lymph from inflammatory sites.

M G Johnston, J B Hay, H Z Movat.   

Abstract

Arachidonic acid labeled with (14)C was injected directly into lymph nodes that had been stimulated at various times with Escherichia coli. The efferent lymph was collected, and labeled catabolites were extracted and analyzed chromatographically. The pimary conversion product recovered was Prostaglandin E(2) (PGE(2)), with the lesser products thromboxane, prostacyclin and prostaglandin F(2alpha) (PGF(2alpha)) also detected. When the efferent lymph was analyzed by radioimmunoassay after subcutaneous injectino of E coli into the hock, PGE and PGF levels rapidly increased, reached the highest levels in the first 10 hours, and then returned to normal by 24 hours. When the afferent lymph plasma draining inflammatory sites was compared directly with efferent lymph, PGF levels were similar, but the PGE level was always several times higher in the afferent lymph. To examine the catabolism of PG, either (3,)H-PGF(2alpha) of (3)H-PGE(2) was injected into the node, and the efferent lymph plasma was analyzed. No conversion of PGF(2alpha) to other products was found. In contrast, catabolic products of PGE(2) were detected. With the use of equilibrium dialysis techniques, the binding of PGE(2) and PGF(2alpha) to proteins in lymph and to bovine serum albumin (BSA), human serum albumin (HSA), and BSA stripped of its fatty acids was established. The binding to lymph proteins correlated with the albumin concentrations in the lymph. This albumin binging probably facilitated the retention and transport of PG in the lymph. PG appears in the lymph at a time corresponding to the uptake and processing of antigen by the node and near the time when lymphokines are detected in lymph and could modulate several steps in the immune response. The PGE detectable in the lymph draining an inflammatory site may play a role in the modulation of blood flow.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992593      PMCID: PMC1903704     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Prostaglandin-macromolecule interactions. I. Noncovalent binding of prostaglandins A1, E1, F2alpha, and E2 by human and bovine serum albumins.

Authors:  F L Gueriguian
Journal:  J Pharmacol Exp Ther       Date:  1976-05       Impact factor: 4.030

2.  The behaviour of the pulmonary metabolites of prostaglandins in several simple thin-layer chromatography and bioassay systems.

Authors:  D J Crutchley; P J Piper
Journal:  Prostaglandins       Date:  1976-06

Review 3.  Antibodies to pharmacologically active molecules: specificities and some applications of antiprostaglandins.

Authors:  L Levine
Journal:  Pharmacol Rev       Date:  1973-06       Impact factor: 25.468

4.  The effect of prostaglandins on the in vitro blastogenic response of human peripheral blood lymphocytes.

Authors:  G D Stockman; D M Mumford
Journal:  Exp Hematol       Date:  1974       Impact factor: 3.084

5.  The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity.

Authors:  L M Lichtenstein; E Gillespie; H R Bourne; C S Henney
Journal:  Prostaglandins       Date:  1972-12

6.  Interaction of prostaglandins with blood plasma proteins. I. Binding of prostaglandin E 2 to human plasma proteins and its effect on the physiological activity of prostaglandin E 2 in vitro and in vivo.

Authors:  A Raz
Journal:  Biochim Biophys Acta       Date:  1972-12-08

7.  Inactivation of prostaglandins by the lungs.

Authors:  P J Piper; J R Vane; J H Wyllie
Journal:  Nature       Date:  1970-02-14       Impact factor: 49.962

8.  Antigen stimulation of prostaglandin synthesis and control of immune responses.

Authors:  D R Webb; P L Osheroff
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

9.  Interaction of prostaglandins with blood plasma proteins. Comparative binding of prostaglandins A 2 , F 2 and E 2 to human plasma proteins.

Authors:  A Raz
Journal:  Biochem J       Date:  1972-11       Impact factor: 3.857

10.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.

Authors:  M Hamberg; J Svensson; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

View more
  7 in total

1.  Chemoattractant receptors and lymphocyte egress from extralymphoid tissue: changing requirements during the course of inflammation.

Authors:  Meghan N Brown; Sarah R Fintushel; Michael H Lee; Silke Jennrich; Skye A Geherin; John B Hay; Eugene C Butcher; Gudrun F Debes
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

2.  Hydrodynamic regulation of lymphatic transport and the impact of aging.

Authors:  Anatoliy A Gashev; David C Zawieja
Journal:  Pathophysiology       Date:  2010-03-11

3.  Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels.

Authors:  Sonia Rehal; Pauline Blanckaert; Simon Roizes; Pierre-Yves von der Weid
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

4.  Contractile physiology of lymphatics.

Authors:  David C Zawieja
Journal:  Lymphat Res Biol       Date:  2009       Impact factor: 2.589

5.  The inhibitory effect of aspirin on lymphatic contractility.

Authors:  J M Allen; E P Burke; M G Johnston; N G McHale
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

6.  Lymphocyte traffic through antigen-stimulated lymph nodes. II. Role of Prostaglandin E2 as a mediator of cell shutdown.

Authors:  J Hopkins; I McConnell; J D Pearson
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

7.  Neutrophils control the magnitude and spread of the immune response in a thromboxane A2-mediated process.

Authors:  Chiao-Wen Yang; Emil R Unanue
Journal:  J Exp Med       Date:  2013-01-21       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.